prikaz prve stranice dokumenta Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
Embargo period 2025-01-01
Scientific paper - Original scientific paper
Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
Expert Opinion on Drug Safety, 22 (2023), 12; 1265-1270. https://doi.org/10.1080/14740338.2023.2234821
Lucijanić, Marko; Bušić, Nikolina; Stojić, Josip; Barišić-Jaman, Mislav; Zagorec, Nikola; Lazibat, Karla; Pasarić, Antica; Vrkljan Vuk, Anamarija; Durlen, Ivan; Mitrović, Joško; Lukšić, Ivica; Baršić, Bruno

Cite this document

Lucijanić, M., Bušić, N., Stojić, J., Barišić Jaman, M., Zagorec, N., Lazibat, K. ... Baršić, B. (2023). Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety, 22. (12), 1265-1270. doi: 10.1080/14740338.2023.2234821

Lucijanić, Marko, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety, vol. 22, no. 12, 2023, pp. 1265-1270. https://doi.org/10.1080/14740338.2023.2234821

Lucijanić, Marko, Nikolina Bušić, Josip Stojić, Mislav Barišić Jaman, Nikola Zagorec, Karla Lazibat, Antica Pasarić, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety 22, no. 12 (2023): 1265-1270. https://doi.org/10.1080/14740338.2023.2234821

Lucijanić, M., et al. (2023) 'Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate', Expert Opinion on Drug Safety, 22(12), pp. 1265-1270. doi: 10.1080/14740338.2023.2234821

Lucijanić M, Bušić N, Stojić J, Barišić Jaman M, Zagorec N, Lazibat K, and sur.. Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety [Internet]. 2023 July 10 [cited 2024 December 20];22(12):1265-1270. doi: 10.1080/14740338.2023.2234821

M. Lucijanić, et al., "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate", Expert Opinion on Drug Safety, vol. 22, no. 12, pp. 1265-1270, July 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:861487. [Accessed: 20 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
AuthorMarko Lucijanić
AuthorNikolina Bušić
AuthorJosip Stojić
AuthorMislav Barišić-Jaman
AuthorNikola Zagorec
AuthorKarla Lazibat
AuthorAntica Pasarić
AuthorAnamarija Vrkljan Vuk
AuthorIvan Durlen
AuthorJoško Mitrović
AuthorIvica Lukšić
AuthorBruno Baršić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Maxillofacial Surgery and Dentistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Abstract (english)
Background: There are uncertainties regarding associations of prior proton pump inhibitor (PPI) use with susceptibility for COVID-19 and risks associated with SARS-CoV-2 infection. We aimed to evaluate the associations of prior PPI use with outcomes in hospitalized patients with COVID-19. Research design and methods: We have retrospectively evaluated a total of 5959 consecutively hospitalized patients with COVID-19 from a tertiary-level institution in the period 3/2020-6/2021. Associations of prior PPI use with outcomes of in-hospital mortality, mechanical ventilation, intensive care unit stay, venous thromboembolism, arterial thrombosis, major bleeding, bacteremia, and Clostridioides difficile infection (C. diff.) were evaluated in entire and case-matched cohorts. Results: Among 5959 evaluated patients, there were 1967 (33%) PPI users. In an entire cohort, prior PPI use was associated with higher in-hospital mortality and higher occurrence of C. diff. Association of prior PPI use with mortality diminished, whereas association with C. diff. persisted after multivariable adjustments. In a matched cohort, prior PPI use was associated only with higher risk of C. diff. but not other outcomes in line with multivariable analysis. Conclusions: Although prior PPI use might not have a significant impact on clinical course and mortality of SARS-CoV-2 infection, it may predispose patients to the development of complications like higher occurrence of C. diff. and thus substantially impact the course of treatment.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleExpert Opinion on Drug Safety
Numberingvol. 22, no. 12, pp. 1265-1270
p-ISSN1474-0338
e-ISSN1744-764X
DOIhttps://doi.org/10.1080/14740338.2023.2234821
URN:NBNurn:nbn:hr:105:861487
Publication2023-07-10
Document URLhttps://www.tandfonline.com/doi/full/10.1080/14740338.2023.2234821
Type of resourceText
Access conditionsEmbargoed access
Embargo expiration date: 2025-01-01
Terms of useLicence In copyright icon
Created on2024-10-21 10:34:08